Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in prevalent and emerging infectious diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator (POB 001) which offers significant opportunity across multiple disease areas. The initial data analysis from its LPS human challenge trial indicates a marked reduction in both systemic and localised inflammatory response in an LPS human challenge trial (full data read-out expected in Q2 2023). Its other product candidates include a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.
Visit the Poolbeg Pharma Plc website here
Follow Poolbeg Pharma on Twitter @PoolbegPharma
- Poolbeg Pharma #POLB August 2023 – CEO Jeremy Skillington talks to Alan Green
- #POLB Poolbeg Pharma PLC – Annual Report & AGM Notice
- #POLB Poolbeg Pharma PLC – Notification of Major Holdings
- #POLB Poolbeg Pharma – POLB 001 Patent Portfolio Strengthened
- Alan Green provides a SoTP valuation for Power Metal Resources #POW & covers Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
- Markets and Stocks January 2023 – Doc Holliday talks to Alan Green
- New Vox Markets Podcast with our CEO Alan Green out now
- #POLB Poolbeg Pharma PLC – Poolbeg identifies novel RSV drug candidates
- #POLB Poolbeg Pharma PLC – Metabolic diseases oral delivery licence signed
- Poolbeg Pharma #POLB – POLB 001 LPS human challenge clinical trial successfully completed & no serious adverse events reported.
- Poolbeg Pharma #POLB – Influenza Artificial Intelligence model build completed & on track to deliver outputs in Q2 2023
- Markets and Stocks – Doc Holliday talks to Alan Green
- #POLB Poolbeg Pharma Plc- Capital Markets Day
- Poolbeg Pharma #POLB – Poolbeg-led consortium awarded EUR 2.3m grant
- Poolbeg Pharma #POLB – Artificial intelligence programme yields multiple novel RSV drug targets
- #POLB Poolbeg Pharma PLC – Upcoming Events
- Poolbeg Pharma #POLB – POLB 001 US Patent update
- Alan Green covers Poolbeg Pharma #POLB & Sovereign Metals #SVML on this week’s Stockbox Research Talks
- Poolbeg Pharma #POLB licence of Melioidosis vaccine candidate
- #POLB Poolbeg Pharma PLC – HC Wainwright Global Investment Conference
- Poolbeg Pharma #POLB – Interim results for the six months to 30 June 2022
- Alan Green discusses #WTB Whitbread, #POLB Poolbeg Pharma & #FCM First Class Metals on the Vox Market Podcast
- A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington
- UK Investor Magazine Podcast – Covering Royal Mail #RMG Poolbeg Pharma #POLB & GreenX Metals #GRX
- Poolbeg Pharma #POLB – Major milestone reached as POLB 001 human challenge clinical trial ready to commence
- News Poolbeg Pharma AI model of respiratory syncytial virus starts analysis
- Poolbeg Pharma #POLB – Article
- #POLB Poolbeg Pharma – US patents granted for POLB 001 and POLB 002
- #POLB Poolbeg Pharma – TR-1: Notification of major interest in shares
- Alan Green covers Amaroq Minerals #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
- #POLB Poolbeg Pharma – GMP manufacturing contract signed
- Poolbeg Pharma #POLB to engage with key international stakeholders at European Melioidosis Congress as it develops an intramuscular Melioidosis vaccine candidate
- Poolbeg Pharma #POLB presenting at LSX Leaders event
- Poolbeg Pharma #POLB – Results of the proposal to purchase shares from Distribution in Specie shareholders
- #POLB Poolbeg Pharma – Key POLB 002 European Patent Granted
- #POLB Poolbeg Pharma – Proposal to Purchase Shares from Distribution in Specie Shareholders
- #POLB Poolbeg Pharma – Result of AGM
- Poolbeg Pharma #POLB – POLB 001 Clinical Development – Clinical Trial Agreement Signed
- Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States
- #POLB Poolbeg Pharma – Artificial Intelligence deal signed with CytoReason
- #ORPH Open Orphan – Open Orphan plc distribution in specie of Poolbeg Pharma plc shares – FAQ
- Alan Green covers #POLB Poolbeg Pharma, #NTOG Nostra Terra O&G and #MNRG MetalNRG on the Vox Market Podcast
- #POLB Poolbeg Pharma – POLB sign AI discovery deal with OneThree Biotech for first human challenge trial
- Poolbeg Pharma #POLB – 2021 Annual Report and 2022 AGM Notice
- #POLB Poolbeg Pharma – Final Results
- Poolbeg Pharma #POLB – Interview
- #POLB Poolbeg Pharma – Notice of Results
- #POLB Poolbeg Pharma – Artificial Intelligence deal with OneThree Biotech
- Poolbeg Pharma #POLB – Article – Further Assets
- Poolbeg Pharma #POLB – Upcoming London Webinar
- Poolbeg Pharma #POLB – sign licence agreement with AnaBio Technologies to develop oral vaccine platform
- #POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution
- Vox Market Podcast – Alan Green discusses Revolution Bars #RGB, Blencowe Resources #BRES & Poolbeg Pharma #POLB
- Poolbeg Pharma #POLB – Licenses RNA-based immunotherapy asset
- Poolbeg Pharma #POLB – Growing a Capital Light Company. CEO Jeremy Skillington talks to Alan Green
- Pharma Times – Poolbeg Pharma dives into nasally administered antivirals
- #POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
- Alan Green covers AEX Gold #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
- Poolbeg Pharma #POLB CEO Jeremy Skillington talks to BRR Media
- #POLB Poolbeg Pharma – Poolbeg to develop oral vaccine delivery platform
- Poolbeg Pharma #POLB – Drug Discovery
- Poolbeg Pharma #POLB – agrees option agreement with UCD
- #POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate
- #POLB Poolbeg Pharma – Shares Spotlight
- #POLB Poolbeg Pharma – Scientific Advisory Board Appointment
- #POLB Poolbeg Pharma – Update on POLB 001 Clinical Development
- Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green
- Alan Green discusses ECR Minerals #ECR, with a tribute to CEO Craig Brown, plus Poolbeg Pharma #POLB on this week’s Stockbox Research talk
- #POLB Poolbeg Pharma – PredictViral™ Patent update
- Poolbeg Pharma #POLB – RNA sequencing ahead of AI analysis programme
- Poolbeg Pharma #POLB – Admission to AIM and First day of trading
- Open Orphan #ORPH – AIM Schedule 1 update by Poolbeg Pharma plc
- The Times – Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy Skillington
